Should I buy or sell Lonza Group stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lonza Group in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LZAGY shares. View LZAGY analyst ratings or view top-rated stocks .

How have LZAGY shares performed in 2024?

Lonza Group's stock was trading at $42.09 at the beginning of 2024. Since then, LZAGY stock has increased by 31.0% and is now trading at $55.15. View the best growth stocks for 2024 here .

Are investors shorting Lonza Group?

Lonza Group saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,800 shares, an increase of 77.8% from the March 15th total of 2,700 shares. Based on an average daily trading volume, of 328,600 shares, the days-to-cover ratio is currently 0.0 days. View Lonza Group's Short Interest .

How often does Lonza Group pay dividends? What is the dividend yield for Lonza Group?

Lonza Group declared a dividend on Thursday, May 4th. Investors of record on Wednesday, May 10th will be paid a dividend of $0.108 per share on Friday, May 26th. This represents a yield of 0.17%. The ex-dividend date of this dividend is Tuesday, May 9th. This is an increase from the stock's previous dividend of $0.09. Read our dividend analysis for LZAGY .

Is Lonza Group a good dividend stock?

Lonza Group (OTCMKTS:LZAGY) pays an annual dividend of $0.09 per share and currently has a dividend yield of 0.15%. Read our dividend analysis for LZAGY .

How do I buy shares of Lonza Group?

Shares of LZAGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Lonza Group have any subsidiaries?

The following companies are subsidiares of Lonza Group: Arch Acquisition LLC, Arch Chemicals Canada Inc., Arch Chemicals Inc., Arch Chemicals Limited, Arch Chemicals Receivables LLC, Arch Chemicals SAS, Arch Personal Care Products L.P., Arch Protection Chemicals Private Limited, Arch Quimica Argentina S.R.L., Arch Quimica Brasil Ltda., Arch Timber Protection B.V., Arch Treatment Technologies Inc., Arch UK Biocides Limited, Arch Water Products France S.A.S., Arch Water Products South Africa (Pty) Ltd, Arch Wood Protection (Aust) Pty Ltd, Arch Wood Protection (M) Sdn. Bhd., Arch Wood Protection (NZ) Limited, Arch Wood Protection (SA) Pty Ltd, Arch Wood Protection Canada Corp., Arch Wood Protection Inc, Bend Research Inc., BioAtrium AG, CH Capsules Malaysia SDN BHD, Capsugel, Capsugel (Thailand) Co. Ltd, Capsugel Australia Pty Ltd, Capsugel Belgium NV, Capsugel Brasil Importação e Distribuição de Insumos Farmacêuticos e Alimentos Ltda., Capsugel Canada Corp., Capsugel Distribucion S. de R.L. de C.V., Capsugel FinanceCo II S.à r.l., Capsugel FinanceCo S.C.A., Capsugel FinanceCo S.à r.l, Capsugel France Holdings SAS, Capsugel France SAS, Capsugel Funding LLC, Capsugel Germany GmbH, Capsugel Healthcare Private Limited, Capsugel Holdings (Hong Kong) Limited, Capsugel Holdings S.à r.l., Capsugel Holdings US Inc., Capsugel Hungary Kft, Capsugel Inc., Capsugel Italy S.R.L., Capsugel Japan Inc., Capsugel Manufacturing Inc., Capsugel Middle East Sàrl, Capsugel New Zealand Limited, Capsugel Pharmaceutical and Health Products Marketing Ltd, Capsugel Philippines Inc., Capsugel Ploermel SAS, Capsugel S.à r.l., Capsugel Spain S.L., Capsugel US LLC, Capsugel de México S. de R.L. de C.V., Diacon Technologies, Diacon Technologies Limited, Hickson Ltd, InterHealth Nutraceuticals, InterHealth Nutraceuticals Incorporated, LLC Capsugel, Lonza (China) Investments Co. Ltd., Lonza AG, Lonza America Inc., Lonza Argentina S.A, Lonza Biologics Inc., Lonza Biologics Porriño S.L., Lonza Biologics Tuas Pte. Ltd, Lonza Biologics plc, Lonza Bioscience SARL, Lonza Bioscience Singapore Pte Ltd, Lonza Biotec s.r.o., Lonza Cologne GmbH, Lonza Colombia S.A.S, Lonza Copenhagen ApS, Lonza Costa Rica S.A., Lonza Geleen B.V., Lonza Guangzhou Ltd, Lonza Guangzhou Nansha Ltd, Lonza Houston Inc., Lonza Inc., Lonza India Private Limited, Lonza Israel Ltd, Lonza Japan Ltd, Lonza Luxembourg S.à r.l., Lonza Microbial Control Asia Pacific Pte Ltd, Lonza Milano S.r.l., Lonza NZ Limited, Lonza Nanjing Ltd, Lonza Netherlands B.V, Lonza Rockland Inc., Lonza Sales AG, Lonza Shanghai International Trading Ltd, Lonza Suzhou Ltd, Lonza Swiss Finanz AG, Lonza Swiss Licences AG, Lonza Verviers SPRL, Lonza Walkersville Inc., Lonza do Brasil Especialidades Quimicas Ltda., MW Encap (Holdings) Limited, MW Encap Limited, Micro-Macinazione, Micro-Macinazione SA, Octane Biotech, Octane Biotech Inc, P.T. Capsugel Indonesia, PharmaCell, Powdersize LLC, Suzhou Capsugel Limited (JV), Triangle Research Labs, Xcelience Clinical Services Ltd, Xcelience LLC, and Zelam Holdings. Read More

OTCMKTS:LZAGY

Lonza Group (LZAGY) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free LZAGY Stock Alerts

$55.15

-0.50 (-0.90%)

(As of 04/19/2024 ET)

Compare

Today's Range: $54.95
▼
$55.41
50-Day Range: $49.65
▼
$61.48
52-Week Range: $34.19
▼
$66.00

Volume: 48,975 shs
Average Volume: 164,733 shs
Market Capitalization: $41.07 billion

P/E Ratio: N/A
Dividend Yield: 0.16%
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Dividend Financials Headlines Insider Trades SEC Filings Short Interest

Get Lonza Group alerts:

Lonza Group MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.00% of Shares Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: 22.30%
From $1.39 to $1.70 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.99 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Lonza Group.

3.0

Short Interest

Percentage of Shares Shorted
0.00% of the outstanding shares of Lonza Group have been sold short.
Short Interest Ratio / Days to Cover
Lonza Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Lonza Group has recently increased by 77.78%, indicating that investor sentiment is decreasing significantly.

0.8

Dividend Strength

Dividend Yield
Lonza Group has a dividend yield of 0.15%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Lonza Group does not have a long track record of dividend growth.
Dividend Sustainability
Based on earnings estimates, Lonza Group will have a dividend payout ratio of 5.29% next year. This indicates that Lonza Group will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LZAGY.

2.9

News and Social Media Coverage

News Sentiment
Lonza Group has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Lonza Group this week, compared to 1 article on an average week.
MarketBeat Follows
72 people have added Lonza Group to their MarketBeat watchlist in the last 30 days. This is an increase of 118% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lonza Group insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.07% of the stock of Lonza Group is held by insiders.
Percentage Held by Institutions
Only 0.04% of the stock of Lonza Group is held by institutions.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Lonza Group are expected to grow by 22.30% in the coming year, from $1.39 to $1.70 per share.
Price to Book Value per Share Ratio
Lonza Group has a P/B Ratio of 3.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Lonza Group Stock (OTCMKTS:LZAGY)

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was incorporated in 1897 and is headquartered in Basel, Switzerland.

LZAGY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LZAGY Stock News Headlines

April 17, 2024 | markets.businessinsider.com

Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon

April 5, 2024 | seekingalpha.com

Lonza: Acceleration In Mid-Term Sales Growth

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 3, 2024 | finance.yahoo.com

Lonza Group AG's (VTX:LONN) largest shareholders are individual investors with 56% ownership, institutions own 44%

April 2, 2024 | finance.yahoo.com

Lonza Taps Siegfried Holding’s Wolfgang Wienand as Next CEO

March 27, 2024 | wsj.com

Lonza Group AG ADR

March 25, 2024 | gurufocus.com

Lonza Group AG Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from ...

March 14, 2024 | finance.yahoo.com

Lonza Group's (VTX:LONN) five-year earnings growth trails the favorable shareholder returns

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

February 25, 2024 | msn.com

Lonza Group (LZAGF) Price Target Increased by 7.21% to 568.67

February 10, 2024 | uk.investing.com

Lonza Group AG (LZAGY)

February 2, 2024 | uk.investing.com

Lonza Group AG (LONNz)

January 28, 2024 | seekingalpha.com

Lonza: Excellent Growth Projections Will Sharply Increase Free Cash Flow

January 27, 2024 | finance.yahoo.com

Lonza Group Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

January 26, 2024 | morningstar.com

Lonza Shares Rise on Sales, Earnings Beat

January 26, 2024 | msn.com

Lonza long-time chairman to exit; shares gain

January 26, 2024 | finance.yahoo.com

UPDATE 2-Lonza chairman to step down, drugmaker confirms targets, shares soar

January 26, 2024 | finance.yahoo.com

Lonza chairman to step down, drugmaker confirms targets, shares soar

January 26, 2024 | finance.yahoo.com

Lonza Sees Flat Sales in 2024

January 19, 2024 | finance.yahoo.com

A Look At The Fair Value Of Lonza Group AG (VTX:LONN)

January 17, 2024 | bizjournals.com

East Bay drug manufacturer to close facility it bought in 2017, cut 218 jobs

November 13, 2023 | finance.yahoo.com

Lonza Group AG (VTX:LONN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

November 10, 2023 | morningstar.com

Lonza Group Ltd ADR LZAGY

November 6, 2023 | markets.businessinsider.com

Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds

November 3, 2023 | morningstar.com

Lonza Group Ltd LONN

October 26, 2023 | finance.yahoo.com

Individual investors who have a significant stake must be disappointed along with institutions after Lonza Group AG's (VTX:LONN) market cap dropped by CHF2.2b

October 5, 2023 | finance.yahoo.com

Investors in Lonza Group (VTX:LONN) have seen respectable returns of 39% over the past five years

See More Headlines

Receive LZAGY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lonza Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Tobacco products
Sub-Industry: N/A
Current Symbol: OTCMKTS:LZAGY
CUSIP: N/A
CIK: 1446711
Web: www.lonza.com
Phone: (161) 316-8111
Fax: 41-61-316-9111
Employees: 17,494
Year Founded: 1897

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.27
Current Ratio: 1.77
Quick Ratio: 1.20

Sales & Book Value

Annual Sales: $7.48 billion
Price / Sales: 5.49
Cash Flow: $1.99 per share
Price / Cash Flow: 27.66
Book Value: $14.23 per share
Price / Book: 3.88

Miscellaneous

Outstanding Shares: 744,690,000
Free Float: 744,167,000
Market Cap: $41.07 billion
Optionable: Not Optionable
Beta: 0.97

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Albert M. Baehny (Age 72)
Interim CEO & Chairman
Comp: $356.82k
Mr. Philippe Deecke (Age 52)
Chief Financial Officer
Ms. Maria Soler Nunez (Age 55)
Head of Group Operations
Mr. Dirk Oehlers
Vice President of Investor Relations
Mr. Andreas Bohrer
Group General Counsel & Company Secretary
Ms. Victoria Morgan
Head of External Communications
Ms. Jennifer Clancy
Senior Director of Global Marketing
Ulrike Kaeppler
Chief Human Resources Officer
Dr. Matthias Hofmann
Head of Corporate Environment, Health, Safety & Global Sustainability
Mr. Jean-Christophe Hyvert (Age 52)
President of Biologics Division

Key Competitors

View All Competitors

Should I Buy Lonza Group Stock? LZAGY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Lonza Group AG:

Lonza reported better-than-expected sales and margins last year, indicating strong financial performance.
The company confirmed its 2024 and mid-term margin targets, showing a clear path for growth and profitability.
Lonza's focus on contract development and manufacturing of biopharmaceuticals positions it well in the pharmaceutical market.
Lonza's technologies and platforms for cell and gene therapies offer a competitive edge in the rapidly growing biotech sector.
With the current stock price performing well, investors may see potential for capital appreciation.

Cons

Investors should be bearish about investing in Lonza Group AG for these reasons:

The loss of COVID-related business may impact Lonza's short-term revenue and profitability.
Senior management reshuffles could introduce uncertainties in the company's strategic direction.
Market volatility and regulatory challenges in the pharmaceutical industry could affect Lonza's operations.
Competition in the contract drug manufacturing space may put pressure on Lonza's market share and pricing.
External factors like global economic conditions could influence Lonza's performance and stock price.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these Lonza Group pros and cons to contact@marketbeat.com.

LZAGY Stock Analysis - Frequently Asked Questions

Should I buy or sell Lonza Group stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lonza Group in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LZAGY shares.
View LZAGY analyst ratings or view top-rated stocks.
How have LZAGY shares performed in 2024?: Lonza Group's stock was trading at $42.09 at the beginning of 2024. Since then, LZAGY stock has increased by 31.0% and is now trading at $55.15.
View the best growth stocks for 2024 here.
Are investors shorting Lonza Group?: Lonza Group saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,800 shares, an increase of 77.8% from the March 15th total of 2,700 shares. Based on an average daily trading volume, of 328,600 shares, the days-to-cover ratio is currently 0.0 days.
View Lonza Group's Short Interest.
How often does Lonza Group pay dividends? What is the dividend yield for Lonza Group?: Lonza Group declared a dividend on Thursday, May 4th. Investors of record on Wednesday, May 10th will be paid a dividend of $0.108 per share on Friday, May 26th. This represents a yield of 0.17%. The ex-dividend date of this dividend is Tuesday, May 9th. This is an increase from the stock's previous dividend of $0.09.
Read our dividend analysis for LZAGY.

Is Lonza Group a good dividend stock?: Lonza Group (OTCMKTS:LZAGY) pays an annual dividend of $0.09 per share and currently has a dividend yield of 0.15%.
Read our dividend analysis for LZAGY.
How do I buy shares of Lonza Group?: Shares of LZAGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Lonza Group have any subsidiaries?: The following companies are subsidiares of Lonza Group: Arch Acquisition LLC, Arch Chemicals Canada Inc., Arch Chemicals Inc., Arch Chemicals Limited, Arch Chemicals Receivables LLC, Arch Chemicals SAS, Arch Personal Care Products L.P., Arch Protection Chemicals Private Limited, Arch Quimica Argentina S.R.L., Arch Quimica Brasil Ltda., Arch Timber Protection B.V., Arch Treatment Technologies Inc., Arch UK Biocides Limited, Arch Water Products France S.A.S., Arch Water Products South Africa (Pty) Ltd, Arch Wood Protection (Aust) Pty Ltd, Arch Wood Protection (M) Sdn. Bhd., Arch Wood Protection (NZ) Limited, Arch Wood Protection (SA) Pty Ltd, Arch Wood Protection Canada Corp., Arch Wood Protection Inc, Bend Research Inc., BioAtrium AG, CH Capsules Malaysia SDN BHD, Capsugel, Capsugel (Thailand) Co. Ltd, Capsugel Australia Pty Ltd, Capsugel Belgium NV, Capsugel Brasil Importação e Distribuição de Insumos Farmacêuticos e Alimentos Ltda., Capsugel Canada Corp., Capsugel Distribucion S. de R.L. de C.V., Capsugel FinanceCo II S.à r.l., Capsugel FinanceCo S.C.A., Capsugel FinanceCo S.à r.l, Capsugel France Holdings SAS, Capsugel France SAS, Capsugel Funding LLC, Capsugel Germany GmbH, Capsugel Healthcare Private Limited, Capsugel Holdings (Hong Kong) Limited, Capsugel Holdings S.à r.l., Capsugel Holdings US Inc., Capsugel Hungary Kft, Capsugel Inc., Capsugel Italy S.R.L., Capsugel Japan Inc., Capsugel Manufacturing Inc., Capsugel Middle East Sàrl, Capsugel New Zealand Limited, Capsugel Pharmaceutical and Health Products Marketing Ltd, Capsugel Philippines Inc., Capsugel Ploermel SAS, Capsugel S.à r.l., Capsugel Spain S.L., Capsugel US LLC, Capsugel de México S. de R.L. de C.V., Diacon Technologies, Diacon Technologies Limited, Hickson Ltd, InterHealth Nutraceuticals, InterHealth Nutraceuticals Incorporated, LLC Capsugel, Lonza (China) Investments Co. Ltd., Lonza AG, Lonza America Inc., Lonza Argentina S.A, Lonza Biologics Inc., Lonza Biologics Porriño S.L., Lonza Biologics Tuas Pte. Ltd, Lonza Biologics plc, Lonza Bioscience SARL, Lonza Bioscience Singapore Pte Ltd, Lonza Biotec s.r.o., Lonza Cologne GmbH, Lonza Colombia S.A.S, Lonza Copenhagen ApS, Lonza Costa Rica S.A., Lonza Geleen B.V., Lonza Guangzhou Ltd, Lonza Guangzhou Nansha Ltd, Lonza Houston Inc., Lonza Inc., Lonza India Private Limited, Lonza Israel Ltd, Lonza Japan Ltd, Lonza Luxembourg S.à r.l., Lonza Microbial Control Asia Pacific Pte Ltd, Lonza Milano S.r.l., Lonza NZ Limited, Lonza Nanjing Ltd, Lonza Netherlands B.V, Lonza Rockland Inc., Lonza Sales AG, Lonza Shanghai International Trading Ltd, Lonza Suzhou Ltd, Lonza Swiss Finanz AG, Lonza Swiss Licences AG, Lonza Verviers SPRL, Lonza Walkersville Inc., Lonza do Brasil Especialidades Quimicas Ltda., MW Encap (Holdings) Limited, MW Encap Limited, Micro-Macinazione, Micro-Macinazione SA, Octane Biotech, Octane Biotech Inc, P.T. Capsugel Indonesia, PharmaCell, Powdersize LLC, Suzhou Capsugel Limited (JV), Triangle Research Labs, Xcelience Clinical Services Ltd, Xcelience LLC, and Zelam Holdings.
Read More

This page (OTCMKTS:LZAGY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Lonza Group (LZAGY) Stock Price, News & Analysis

Lonza Group MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Lonza Group Stock (OTCMKTS:LZAGY)

LZAGY Stock Price History

LZAGY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Should I Buy Lonza Group Stock? LZAGY Pros and Cons Explained

Pros

Cons

LZAGY Stock Analysis - Frequently Asked Questions

Overall MarketRank^™